Follow
Bryan Chang
Title
Cited by
Cited by
Year
Predicting PDZ domain–peptide interactions from primary sequences
JR Chen, BH Chang, JE Allen, MA Stiffler, G MacBeath
Nature biotechnology 26 (9), 1041-1045, 2008
1732008
Quantifying protein–protein interactions in high throughput using protein domain microarrays
A Kaushansky, JE Allen, A Gordus, MA Stiffler, ES Karp, BH Chang, ...
Nature protocols 5 (4), 773-790, 2010
852010
A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R
A Kaushansky, A Gordus, B Chang, J Rush, G MacBeath
Molecular Biosystems 4 (6), 643-653, 2008
682008
Linear combinations of docking affinities explain quantitative differences in RTK signaling
A Gordus, JA Krall, EM Beyer, A Kaushansky, A Wolf‐Yadlin, M Sevecka, ...
Molecular systems biology 5 (1), 235, 2009
672009
A systematic family-wide investigation reveals that∼ 30% of mammalian PDZ domains engage in PDZ-PDZ interactions
BH Chang, TS Gujral, ES Karp, R BuKhalid, VP Grantcharova, ...
Chemistry & biology 18 (9), 1143-1152, 2011
602011
Family-wide investigation of PDZ domain-mediated protein-protein interactions implicates β-catenin in maintaining the integrity of tight junctions
TS Gujral, ES Karp, M Chan, BH Chang, G MacBeath
Chemistry & biology 20 (6), 816-827, 2013
402013
An N1–Hydrogen bonding model for flavin coenzyme
F Guo, BH Chang, CJ Rizzo
Bioorganic & medicinal chemistry letters 12 (2), 151-154, 2002
352002
Guanidino compounds
D Chu, RS Boyce, D Duhl, BH Chang
US Patent 6,716,840, 2004
332004
Corrigendum: Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina)
D Martinez, RM Berka, B Henrissat, M Saloheimo, M Arvas, SE Baker, ...
Nature Biotechnology 26 (10), 2008
222008
Substituted quinazolinone compounds
RS Boyce, N Aurrecoechea, D Chu, A Smith, B Chang
US Patent 7,034,033, 2006
202006
Guanidino compounds
D Chu, R Boyce, D Duhl, B Chang
US Patent 7,456,183, 2008
192008
Evaluation of the anti-PD-1 flare response in patients with advanced melanoma using FDG PET/CT imaging and hematologic biomarkers
B Chang, A Huang, C Shang, K Palmer, E Schubert, W Xu, R Amaravadi, ...
Journal of Nuclear Medicine 60 (supplement 1), 1270-1270, 2019
142019
Using CD69 PET imaging to monitor immunotherapy-induced immune activation
KJ Edwards, B Chang, H Babazada, K Lohith, DH Park, MD Farwell, ...
Cancer immunology research 10 (9), 1084-1094, 2022
112022
Development of a HER3 PET probe for breast cancer imaging
E Wehrenberg-Klee, NS Turker, B Chang, P Heidari, U Mahmood
Journal of Nuclear Medicine 55 (supplement 1), 550-550, 2014
102014
Substituted dihydroisoquinolinone compounds
RS Boyce, N Aurrecoechea, D Chu, A Smith, B Chang
US Patent 7,858,641, 2010
62010
Substituted pyrido [2, 3-d] pyrimidinone compounds
RS Boyce, N Aurrecoechea, D Chu, A Smith, B Chang
US Patent 7,858,631, 2010
52010
Compositions and Methods for Viral Inhibition
ZJ Ni, B Chang, W Wang, A Weiner
US Patent App. 10/576,045, 2007
32007
FDG PET/CT Imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma
TM Anderson, BH Chang, AC Huang, X Xu, D Yoon, CG Shang, R Mick, ...
Clinical Cancer Research 30 (9), 1758-1767, 2024
22024
Tracking Engineered T Cell Therapies with an RNA-based Reporter Gene
B Chang, C Shang, K Lohith, M Farwell
Journal of Nuclear Medicine 60 (supplement 1), 1605-1605, 2019
22019
Lactam containing hcv inhibitors
P Barsanti, N Brammier, B Chang, ZJ Ni, W Wang, A Weiner
US Patent App. 11/917,299, 2009
12009
The system can't perform the operation now. Try again later.
Articles 1–20